Genomic rearrangement associated with prostate cancer and methods of using the genomic rearrangement

摘要

The present disclosure provides for a genomic rearrangement of the chromosome 3q13 region associated with prostate cancer, for example, a gene fusion between the ZBTB20 gene and the LSAMP gene and a rearrangement between the ZBTB20 gene and the LSAMP gene, including a deletion spanning both genes. Provide organization. The ZBTB20 / LSAMP genome rearrangement serves as a biomarker for prostate cancer, to stratify prostate cancer based on ethnicity or prostate cancer severity or pathogenicity and / or for prostate cancer treatment Can be used to identify. Another aspect relates to the discovery that deletion of the PTEN gene is observed primarily in prostate cancer from Caucasian subjects. Also provided are kits for prostate cancer diagnosis and prognosis determination. [Selection] Figure 1